Skye Bioscience公布新型肥胖症疗法：靶向CB1抗体突破GLP-1药物局限

华尔街洞察

Jul 16, 2025

Skye Bioscience近日发布最新研发进展报告，披露其在代谢疾病治疗领域的突破性成果。报告重点展示其核心候选药物Nimacimab——一款靶向大麻素受体CB1的单克隆抗体，有望为现有GLP-1类药物疗法失效的患者群体提供全新解决方案。

该抗体疗法具有双重临床价值：不仅适用于对GLP-1类药物产生耐药性或无法耐受副作用的患者群体，还可作为联合治疗方案增强减重效果。区别于当前主流GLP-1药物的作用机制，Nimacimab通过调节能量代谢核心通路，直接激活脂肪组织消耗路径，在增加能量消耗的同时靶向减少脂肪质量。

研发管线显示，除CB1靶点外，公司同步推进Activin、肌生长抑制素及Apelin等多靶点开发策略，旨在解决代谢疾病的根本驱动因素。值得注意的是，当前以Wegovy®和Zepbound®为代表的GLP-1药物虽占据市场主导，但普遍存在胃肠道不良反应及患者依从性难题，这为新型替代疗法创造显著临床需求。

完整技术报告已通过公司官网渠道发布，其中包含详细的临床前数据及作用机制图解。该疗法若研发成功，或将重塑超200亿美元规模的肥胖症治疗市场格局。

（免责声明：本资讯基于人工智能技术生成，仅作信息参考之用，不构成任何投资建议。原始内容由Skye Bioscience于2025年7月16日发布，相关信息准确性由发布方全权负责。）

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1112195175"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1112195175\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1112195175?lang=en_US&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2025-07-16 08:53","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1112195175","market":"hk","top_or_hot":-1,"title":"Skye Bioscience公布新型肥胖症疗法：靶向CB1抗体突破GLP-1药物局限","media":"华尔街洞察","content":"<p>Skye Bioscience近日发布最新研发进展报告，披露其在代谢疾病治疗领域的突破性成果。报告重点展示其核心候选药物Nimacimab——一款靶向大麻素受体CB1的单克隆抗体，有望为现有GLP-1类药物疗法失效的患者群体提供全新解决方案。</p>\n<p>该抗体疗法具有双重临床价值：不仅适用于对GLP-1类药物产生耐药性或无法耐受副作用的患者群体，还可作为联合治疗方案增强减重效果。区别于当前主流GLP-1药物的作用机制，Nimacimab通过调节能量代谢核心通路，直接激活脂肪组织消耗路径，在增加能量消耗的同时靶向减少脂肪质量。</p>\n<p>研发管线显示，除CB1靶点外，公司同步推进Activin、肌生长抑制素及Apelin等多靶点开发策略，旨在解决代谢疾病的根本驱动因素。值得注意的是，当前以Wegovy®和Zepbound®为代表的GLP-1药物虽占据市场主导，但普遍存在胃肠道不良反应及患者依从性难题，这为新型替代疗法创造显著临床需求。</p>\n<p>完整技术报告已通过公司官网渠道发布，其中包含详细的临床前数据及作用机制图解。该疗法若研发成功，或将重塑超200亿美元规模的肥胖症治疗市场格局。</p>\n<p>（免责声明：本资讯基于人工智能技术生成，仅作信息参考之用，不构成任何投资建议。原始内容由Skye Bioscience于2025年7月16日发布，相关信息准确性由发布方全权负责。）</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Skye Bioscience公布新型肥胖症疗法：靶向CB1抗体突破GLP-1药物局限</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSkye Bioscience公布新型肥胖症疗法：靶向CB1抗体突破GLP-1药物局限\n</h2>\n\n<h4 class=\"meta\">\n\n2025-07-16 08:53 北京时间&nbsp;&nbsp;&nbsp;<strong>华尔街洞察</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Skye Bioscience近日发布最新研发进展报告，披露其在代谢疾病治疗领域的突破性成果。报告重点展示其核心候选药物Nimacimab——一款靶向大麻素受体CB1的单克隆抗体，有望为现有GLP-1类药物疗法失效的患者群体提供全新解决方案。\n该抗体疗法具有双重临床价值：不仅适用于对GLP-1类药物产生耐药性或无法耐受副作用的患者群体，还可作为联合治疗方案增强减重效果。区别于当前主流GLP-1药物...</p>\n\n<a href=\"\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SKYE","symbol_name":"Skye Bioscience Inc.","start_time":0,"source_url":"","article_id":"1112195175","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1112195175","pubTimestamp":1752627239,"columns":[],"sourceInfo":null,"weMediaInfo":null,"summary":"Skye Bioscience近日发布最新研发进展报告，披露其在代谢疾病治疗领域的突破性成果。报告重点展示其核心候选药物Nimacimab——一款靶向大麻素受体CB1的单克隆抗体，有望为现有GLP-1类药物疗法失效的患者群体提供全新解决方案。该抗体疗法具有双重临床价值：不仅适用于对GLP-1类药物产生耐药性或无法耐受副作用的患者群体，还可作为联合治疗方案增强减重效果。原始内容由Skye Bioscience于2025年7月16日发布，相关信息准确性由发布方全权负责。","collect":0,"end_time":0,"defaultTopTitle":"laohu8.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"SKYE":"Skye Bioscience Inc.","BK4139":"生物科技"},"translate_title":"Skye Bioscience announces new obesity therapy: targeted CB1 antibody breaks through the limitations of GLP-1 drugs","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SKYE":1},"content_text":"Skye Bioscience近日发布最新研发进展报告，披露其在代谢疾病治疗领域的突破性成果。报告重点展示其核心候选药物Nimacimab——一款靶向大麻素受体CB1的单克隆抗体，有望为现有GLP-1类药物疗法失效的患者群体提供全新解决方案。\n该抗体疗法具有双重临床价值：不仅适用于对GLP-1类药物产生耐药性或无法耐受副作用的患者群体，还可作为联合治疗方案增强减重效果。区别于当前主流GLP-1药物的作用机制，Nimacimab通过调节能量代谢核心通路，直接激活脂肪组织消耗路径，在增加能量消耗的同时靶向减少脂肪质量。\n研发管线显示，除CB1靶点外，公司同步推进Activin、肌生长抑制素及Apelin等多靶点开发策略，旨在解决代谢疾病的根本驱动因素。值得注意的是，当前以Wegovy®和Zepbound®为代表的GLP-1药物虽占据市场主导，但普遍存在胃肠道不良反应及患者依从性难题，这为新型替代疗法创造显著临床需求。\n完整技术报告已通过公司官网渠道发布，其中包含详细的临床前数据及作用机制图解。该疗法若研发成功，或将重塑超200亿美元规模的肥胖症治疗市场格局。\n（免责声明：本资讯基于人工智能技术生成，仅作信息参考之用，不构成任何投资建议。原始内容由Skye Bioscience于2025年7月16日发布，相关信息准确性由发布方全权负责。）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}